Hub : Traits :

Worry too long after embarrassment

207 significantly associated models · 49 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	209867116	210585575	1	1	2.5e-07	2.0e-07	1.0e+00	100	SYT14
2	3	35439546	36079910	1	1	1.8e-10	7.0e-13	3.6e-04	75	ARPP21
3	3	135273949	137261517	5	1	1.2e-09	9.6e-10	1.0e+00	100	PCCB
4	5	106500969	108412472	1	1	1.8e-08	6.7e-08	7.8e-02	89	FBXL17
5	5	138933151	140378983	1	1	2.3e-07	7.7e-08	1.2e-01	92	PFDN1
6	8	8092025	11891593	18	1	5.4e-13	3.8e-13	1.9e-02	90	XKR6
7	9	127218258	128824378	3	1	8.3e-10	3.7e-09	1.0e-01	92	PRPS1P2
8	11	12611333	14105497	1	1	5.7e-18	1.8e-21	4.8e-05	82	ARNTL
9	11	56716782	58178587	4	1	1.8e-10	7.8e-11	2.7e-02	88	ZDHHC5
10	11	112486568	113952419	3	2	1.5e-10	4.0e-11	3.7e-01	98	DRD2 TTC12
11	13	110849169	112251122	1	1	2.0e-07	7.1e-07	2.4e-01	94	ANKRD10-IT1
12	16	89375239	90172696	4	1	1.2e-09	4.1e-07	9.5e-01	100	DBNDD1
13	17	1584324	3000009	3	1	2.1e-08	2.2e-07	9.5e-01	100	MNT
14	19	13505333	14978284	2	1	1.3e-07	1.3e-07	1.0e+00	100	PRKACA

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder or Schizophrenia	1.99	2	0	0.0	0.00	1.0e+00	DRD2 PCCB
Depressed Affect (Nagel 2018)	7.09	7	3	6.7	0.94	1.6e-03	ARNTL ARPP21 DRD2 FBXL17 PCCB TTC12 ZDHHC5
Depression (Nagel 2018)	5.23	4	2	4.4	0.99	6.0e-03	DRD2 PCCB TTC12 ZDHHC5
Intelligence (Savage-Jansen 2018)	2.43	3	1	2.2	0.00	1.0e+00	PCCB PFDN1 ZDHHC5
Neuroticism (Nagel 2018)	12.91	11	7	15.6	0.99	2.2e-08	ANKRD10-IT1 ARNTL ARPP21 DRD2 FBXL17 MNT PCCB PRPS1P2 SYT14 TTC12 ZDHHC5
Schizophrenia (2018)	2.72	3	1	2.2	0.00	1.0e+00	DRD2 PCCB ZDHHC5
Schizophrenia vs Biploar Disorder	3.37	1	0	0.0	0.00	1.0e+00	ARNTL
Worry (Nagel 2018)	7.91	9	4	8.9	0.97	8.9e-06	ARNTL ARPP21 DRD2 FBXL17 PCCB PRPS1P2 SYT14 TTC12 ZDHHC5
Major Depression (MDD)	3.62	1	0	0.0	0.00	1.0e+00	ZDHHC5
Reaction Time	2.58	1	1	2.2	0.00	1.0e+00	PFDN1
Verbal and Numeric Reasoning (VNR)	2.38	2	1	2.2	0.00	1.0e+00	PFDN1 ZDHHC5
Lupus	1.74	1	0	0.0	0.00	1.0e+00	XKR6
Neuroticism (2016)	9.31	6	1	2.2	0.97	1.7e-03	ARNTL DRD2 MNT PCCB TTC12 XKR6
Schizophrenia (2014)	3.04	3	1	2.2	0.00	1.0e+00	DRD2 PCCB ZDHHC5
Blood Eosinophil Count	0.48	1	0	0.0	0.00	1.0e+00	FBXL17
Blood Platelet Count	1.07	3	3	6.7	0.00	1.0e+00	MNT PCCB ZDHHC5
Blood Red Count	1.06	6	2	4.4	-0.19	7.2e-01	ANKRD10-IT1 ARNTL DRD2 MNT SYT14 ZDHHC5
Blood White Count	0.77	3	0	0.0	0.00	1.0e+00	PCCB PRPS1P2 TTC12
Heel T-Score	0.92	4	0	0.0	0.06	9.4e-01	DBNDD1 MNT SYT14 ZDHHC5
BMI	2.68	5	4	8.9	-0.59	2.9e-01	ARNTL ARPP21 PFDN1 SYT14 TTC12
Height	0.81	3	2	4.4	0.00	1.0e+00	DBNDD1 PCCB PRKACA
Waist Hip Ratio (WHR)	1.62	3	1	2.2	0.00	1.0e+00	PCCB PRPS1P2 TTC12
Systolic Blood Pressure	1.98	3	3	6.7	0.00	1.0e+00	ARNTL PRPS1P2 ZDHHC5
Smoking Status	2.67	2	1	2.2	0.00	1.0e+00	PRPS1P2 SYT14
Cardiovascular Disease	1.93	4	0	0.0	-0.53	4.7e-01	ARNTL DRD2 PCCB TTC12
Lung FEV1/FVC ratio	0.66	1	0	0.0	0.00	1.0e+00	ZDHHC5
Lung FVC	1.17	1	1	2.2	0.00	1.0e+00	SYT14
Neuroticism	12.77	10	7	15.6	0.98	9.5e-07	ARNTL ARPP21 DRD2 FBXL17 MNT PCCB PFDN1 PRPS1P2 TTC12 ZDHHC5
Hair Pigment	96.40	1	1	2.2	0.00	1.0e+00	DBNDD1
Tanning	88.36	2	1	2.2	0.00	1.0e+00	DBNDD1 PFDN1
Hand grip strength (left)	2.06	2	0	0.0	0.00	1.0e+00	ARPP21 PRKACA
Number of treatments/medications taken	1.68	1	0	0.0	0.00	1.0e+00	TTC12
Sensitivity / hurt feelings	7.93	6	3	6.7	0.99	2.4e-04	DRD2 PCCB PRPS1P2 TTC12 XKR6 ZDHHC5
Frequency of depressed mood in last 2 weeks	4.88	3	0	0.0	0.00	1.0e+00	DRD2 PCCB ZDHHC5
Hearing difficulty/problems: Yes	3.10	1	0	0.0	0.00	1.0e+00	FBXL17
Relative age of first facial hair	3.13	1	1	2.2	0.00	1.0e+00	DBNDD1
Other serious medical condition/disability diagnosed by doctor	2.96	2	0	0.0	0.00	1.0e+00	ANKRD10-IT1 TTC12
Systolic blood pressure, automated reading	2.82	4	1	2.2	-0.98	1.8e-02	ARNTL PRPS1P2 XKR6 ZDHHC5
Pack years adult smoking proportion	2.96	1	0	0.0	0.00	1.0e+00	MNT
Impedance of leg (right)	3.17	5	3	6.7	0.68	2.1e-01	DBNDD1 MNT PFDN1 PRPS1P2 XKR6
Leg fat-free mass (left)	1.64	3	2	4.4	0.00	1.0e+00	PRPS1P2 SYT14 XKR6
Trunk fat percentage	2.87	6	0	0.0	-0.10	8.6e-01	ARNTL ARPP21 MNT SYT14 TTC12 ZDHHC5
Hand grip strength (right)	1.64	1	0	0.0	0.00	1.0e+00	ARPP21
Current tobacco smoking	3.19	2	0	0.0	0.00	1.0e+00	PRPS1P2 XKR6
Fed-up feelings	7.01	7	3	6.7	0.99	4.6e-05	ANKRD10-IT1 ARNTL DRD2 PCCB TTC12 XKR6 ZDHHC5
Frequency of unenthusiasm / disinterest in last 2 weeks	5.20	4	0	0.0	1.00	5.6e-04	DRD2 PCCB TTC12 ZDHHC5
Relative age voice broke	2.25	2	0	0.0	0.00	1.0e+00	DBNDD1 PCCB
Age when periods started (menarche)	1.62	1	1	2.2	0.00	1.0e+00	ARNTL
Heel bone mineral density (BMD) T-score, automated (left)	3.15	1	1	2.2	0.00	1.0e+00	XKR6
High blood pressure	3.07	3	1	2.2	0.00	1.0e+00	ARNTL DBNDD1 XKR6
Stomach or abdominal pain in last month	1.75	1	0	0.0	0.00	1.0e+00	PCCB
Medication: Levothyroxine sodium	1.06	1	0	0.0	0.00	1.0e+00	XKR6
Sitting height	1.04	4	1	2.2	-1.00	2.4e-03	DBNDD1 PRKACA PRPS1P2 ZDHHC5
Body mass index (BMI)	3.43	5	4	8.9	-0.86	5.8e-02	ARNTL ARPP21 PFDN1 SYT14 XKR6
Impedance of leg (left)	3.17	5	3	6.7	0.70	1.9e-01	DBNDD1 MNT PFDN1 PRPS1P2 XKR6
Leg predicted mass (left)	1.66	3	2	4.4	0.00	1.0e+00	PRPS1P2 SYT14 XKR6
Trunk fat mass	2.67	6	1	2.2	-0.56	2.5e-01	ARNTL ARPP21 SYT14 TTC12 XKR6 ZDHHC5
Waist circumference	2.75	4	2	4.4	-0.60	4.0e-01	ARNTL ARPP21 SYT14 TTC12
Past tobacco smoking	2.91	2	0	0.0	0.00	1.0e+00	ANKRD10-IT1 PRPS1P2
Alcohol usually taken with meals	5.29	2	1	2.2	0.00	1.0e+00	MNT ZDHHC5
Nervous feelings	9.17	6	2	4.4	0.97	1.7e-03	ANKRD10-IT1 ARNTL PCCB PRPS1P2 TTC12 XKR6
Frequency of tenseness / restlessness in last 2 weeks	5.44	3	1	2.2	0.00	1.0e+00	DRD2 PCCB TTC12
Hearing difficulty/problems with background noise	2.46	1	0	0.0	0.00	1.0e+00	TTC12
Forced vital capacity (FVC)	1.29	2	0	0.0	0.00	1.0e+00	DBNDD1 SYT14
Heel bone mineral density (BMD) T-score, automated (right)	3.09	2	1	2.2	0.00	1.0e+00	DBNDD1 XKR6
Qualifications: None of the above	1.70	1	0	0.0	0.00	1.0e+00	ZDHHC5
Financial difficulties in last 2 years	2.89	1	0	0.0	0.00	1.0e+00	DRD2
Fluid intelligence score	2.00	2	0	0.0	0.00	1.0e+00	PCCB PFDN1
Neuroticism score	15.42	11	8	17.8	0.97	4.0e-07	ANKRD10-IT1 ARNTL ARPP21 DRD2 FBXL17 MNT PCCB PRPS1P2 TTC12 XKR6 ZDHHC5
Weight	2.11	5	2	4.4	-0.78	1.2e-01	ARNTL ARPP21 SYT14 TTC12 XKR6
Impedance of arm (right)	2.50	5	1	2.2	0.68	2.1e-01	DBNDD1 PFDN1 PRPS1P2 XKR6 ZDHHC5
Arm fat percentage (right)	3.52	7	4	8.9	-0.32	4.9e-01	ARNTL ARPP21 PRKACA SYT14 TTC12 XKR6 ZDHHC5
Trunk fat-free mass	1.24	2	1	2.2	0.00	1.0e+00	PRPS1P2 XKR6
Hip circumference	2.20	3	1	2.2	0.00	1.0e+00	SYT14 TTC12 XKR6
Father's age at death	1.37	1	0	0.0	0.00	1.0e+00	XKR6
Worrier / anxious feelings	10.43	8	3	6.7	0.96	1.1e-04	ARNTL ARPP21 DRD2 FBXL17 PCCB PRPS1P2 XKR6 ZDHHC5
Frequency of tiredness / lethargy in last 2 weeks	5.06	4	1	2.2	1.00	2.8e-03	DRD2 MNT TTC12 ZDHHC5
Number of live births	1.31	1	0	0.0	0.00	1.0e+00	DBNDD1
Forced expiratory volume in 1-second (FEV1)	1.34	1	0	0.0	0.00	1.0e+00	PRPS1P2
Serious illness, injury or assault of a close relative in last 2 years	2.28	1	0	0.0	0.00	1.0e+00	XKR6
Impedance of arm (left)	2.19	5	1	2.2	0.63	2.5e-01	DBNDD1 PFDN1 PRPS1P2 XKR6 ZDHHC5
Arm fat mass (right)	3.28	6	4	8.9	-0.67	1.5e-01	ARNTL ARPP21 SYT14 TTC12 XKR6 ZDHHC5
Trunk predicted mass	1.26	2	1	2.2	0.00	1.0e+00	PRPS1P2 XKR6
Standing height	1.03	2	1	2.2	0.00	1.0e+00	DBNDD1 PRKACA
Tense / 'highly strung'	7.79	5	1	2.2	1.00	1.5e-04	DRD2 FBXL17 PCCB TTC12 XKR6
Seen doctor (GP) for nerves, anxiety, tension or depression	4.50	3	1	2.2	0.00	1.0e+00	DRD2 TTC12 ZDHHC5
Hair/balding pattern: Pattern 4	1.60	2	0	0.0	0.00	1.0e+00	DBNDD1 SYT14
Peak expiratory flow (PEF)	2.31	2	0	0.0	0.00	1.0e+00	PRPS1P2 XKR6
Headache pain in last month	2.23	1	0	0.0	0.00	1.0e+00	ZDHHC5
Hypothyroidism/myxoedema (self-reported)	1.65	1	1	2.2	0.00	1.0e+00	XKR6
Body fat percentage	3.15	6	1	2.2	-0.10	8.4e-01	ARNTL ARPP21 MNT SYT14 TTC12 ZDHHC5
Leg fat percentage (right)	3.11	6	1	2.2	-0.38	4.5e-01	ARNTL ARPP21 MNT SYT14 TTC12 XKR6
Arm fat-free mass (right)	1.45	2	2	4.4	0.00	1.0e+00	PRPS1P2 XKR6
Comparative body size at age 10	2.50	2	1	2.2	0.00	1.0e+00	PRKACA XKR6
Number of full brothers	2.27	1	0	0.0	0.00	1.0e+00	ARPP21
Wheeze or whistling in the chest in last year	1.86	1	0	0.0	0.00	1.0e+00	TTC12
Health satisfaction	2.79	1	0	0.0	0.00	1.0e+00	DRD2
Qualifications: College or University degree	1.99	3	1	2.2	0.00	1.0e+00	MNT PFDN1 ZDHHC5
Medication: Blood pressure	1.62	1	0	0.0	0.00	1.0e+00	XKR6
Mean time to correctly identify matches	2.96	1	1	2.2	0.00	1.0e+00	PFDN1
Whole body fat mass	2.90	5	1	2.2	-0.70	1.9e-01	ARNTL ARPP21 SYT14 TTC12 XKR6
Leg fat mass (right)	3.19	5	3	6.7	-0.73	1.6e-01	ARNTL ARPP21 SYT14 TTC12 XKR6
Arm predicted mass (right)	1.50	2	2	4.4	0.00	1.0e+00	PRPS1P2 XKR6
Pulse rate, automated reading	1.51	1	0	0.0	0.00	1.0e+00	ZDHHC5
Alcohol intake frequency.	2.69	4	0	0.0	-0.58	4.2e-01	DRD2 SYT14 TTC12 ZDHHC5
Comparative height size at age 10	0.68	2	0	0.0	0.00	1.0e+00	PCCB TTC12
Suffer from 'nerves'	5.77	4	1	2.2	1.00	2.7e-03	DRD2 FBXL17 TTC12 XKR6
Overall health rating	3.57	4	1	2.2	0.58	4.2e-01	DRD2 MNT TTC12 XKR6
Hypertension (Self-reported)	3.11	3	1	2.2	0.00	1.0e+00	ARNTL DBNDD1 XKR6
Whole body fat-free mass	1.37	2	2	4.4	0.00	1.0e+00	PRPS1P2 XKR6
Leg fat-free mass (right)	1.60	3	2	4.4	0.00	1.0e+00	PRPS1P2 SYT14 XKR6
Arm fat percentage (left)	3.51	6	4	8.9	-0.61	2.0e-01	ARNTL ARPP21 SYT14 TTC12 XKR6 ZDHHC5
Average weekly red wine intake	3.34	2	0	0.0	0.00	1.0e+00	MNT ZDHHC5
Mood swings	6.18	4	3	6.7	0.98	1.6e-02	DRD2 TTC12 XKR6 ZDHHC5
Loneliness, isolation	3.74	1	0	0.0	0.00	1.0e+00	ARNTL
Long-standing illness, disability or infirmity	1.82	1	0	0.0	0.00	1.0e+00	TTC12
Medication for cholesterol	1.66	1	0	0.0	0.00	1.0e+00	XKR6
Smoking status: Current	3.26	2	0	0.0	0.00	1.0e+00	PRPS1P2 XKR6
Whole body water mass	1.37	2	2	4.4	0.00	1.0e+00	PRPS1P2 XKR6
Leg predicted mass (right)	1.59	3	2	4.4	0.00	1.0e+00	PRPS1P2 SYT14 XKR6
Arm fat mass (left)	3.24	5	4	8.9	-0.77	1.3e-01	ARNTL ARPP21 SYT14 TTC12 XKR6
Number of self-reported non-cancer illnesses	2.12	2	0	0.0	0.00	1.0e+00	ARNTL TTC12
Miserableness	7.45	6	3	6.7	0.96	3.0e-03	ARNTL ARPP21 DRD2 PCCB TTC12 XKR6
Guilty feelings	10.61	7	3	6.7	0.97	2.1e-04	ARNTL ARPP21 DRD2 PFDN1 TTC12 XKR6 ZDHHC5
Medication: Blood pressure	2.83	1	1	2.2	0.00	1.0e+00	XKR6
Medication: Bendroflumethiazide	2.93	1	1	2.2	0.00	1.0e+00	XKR6
Ever smoked	2.76	1	0	0.0	0.00	1.0e+00	PRPS1P2
Basal metabolic rate	1.51	3	2	4.4	0.00	1.0e+00	PRPS1P2 SYT14 XKR6
Leg fat percentage (left)	3.21	6	1	2.2	-0.40	4.3e-01	ARNTL ARPP21 MNT SYT14 TTC12 XKR6
Arm fat-free mass (left)	1.39	2	1	2.2	0.00	1.0e+00	PRPS1P2 XKR6
Average weekly beer plus cider intake	2.39	1	0	0.0	0.00	1.0e+00	XKR6
Irritability	7.52	5	1	2.2	0.99	1.1e-03	ANKRD10-IT1 ARPP21 DRD2 FBXL17 XKR6
Risk taking	2.93	2	0	0.0	0.00	1.0e+00	PCCB XKR6
Diastolic blood pressure, automated reading	2.34	2	2	4.4	0.00	1.0e+00	ARNTL XKR6
Unable to work because of sickness or disability	3.28	2	0	0.0	0.00	1.0e+00	ARPP21 ZDHHC5
Commuting to job workplace: Cycle	2.01	1	0	0.0	0.00	1.0e+00	MNT
Vascular/heart problems diagnosed by doctor	2.75	3	1	2.2	0.00	1.0e+00	ARNTL DBNDD1 XKR6
Basal cell carcinoma (self-reported)	4.49	1	1	2.2	0.00	1.0e+00	DBNDD1
Pack years of smoking	2.82	1	0	0.0	0.00	1.0e+00	MNT
Impedance of whole body	2.87	5	3	6.7	0.49	4.0e-01	DBNDD1 MNT PFDN1 PRPS1P2 XKR6
Leg fat mass (left)	3.17	5	3	6.7	-0.73	1.6e-01	ARNTL ARPP21 SYT14 TTC12 XKR6
Arm predicted mass (left)	1.47	2	2	4.4	0.00	1.0e+00	PRPS1P2 XKR6

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	2	0.057	1.7
GTEx	Adipose Visceral Omentum	3	0.147	1.7
GTEx	Adrenal Gland	2	0.137	1.8
GTEx	Artery Aorta	4	0.134	1.8
GTEx	Artery Coronary	2	0.169	1.8
GTEx	Artery Tibial	4	0.106	1.7
GTEx	Brain Caudate basal ganglia	1	0.109	1.8
GTEx	Brain Cerebellar Hemisphere	2	0.134	1.8
GTEx	Brain Cerebellum	3	0.151	1.7
GTEx	Brain Cortex	1	0.097	1.9
GTEx	Brain Frontal Cortex BA9	1	0.108	1.8
GTEx	Brain Hippocampus	0	0.000	1.7
GTEx	Brain Hypothalamus	0	0.000	1.8
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.8
GTEx	Brain Putamen basal ganglia	1	0.160	1.8
GTEx	Breast Mammary Tissue	4	0.203	1.8
GTEx	Breast Mammary Tissue (Male)	2	0.168	1.7
GTEx	Breast Mammary Tissue (Female)	2	0.122	1.7
GTEx	Cells EBV-transformed lymphocytes	2	0.141	1.8
GTEx	Cells Transformed fibroblasts	3	0.071	1.7
GTEx	Colon Sigmoid	4	0.274	1.8
GTEx	Colon Transverse	5	0.242	1.8
GTEx	Esophagus Gastroesophageal Junction	2	0.138	1.9
GTEx	Esophagus Mucosa	7	0.211	1.7
GTEx	Esophagus Muscularis	4	0.124	1.8
GTEx	Heart Atrial Appendage	3	0.190	1.8
GTEx	Heart Left Ventricle	4	0.261	1.8
GTEx	Liver	0	0.000	1.6
GTEx	Lung	6	0.209	1.7
GTEx	Muscle Skeletal	4	0.138	1.7
GTEx	Nerve Tibial	4	0.093	1.7
GTEx	Ovary	0	0.000	1.9
GTEx	Pancreas	5	0.306	1.8
GTEx	Pituitary	1	0.090	1.7
GTEx	Prostate	1	0.120	1.8
GTEx	Skin Not Sun Exposed Suprapubic	5	0.203	1.8
GTEx	Skin Sun Exposed Lower leg	6	0.165	1.7
GTEx	Small Intestine Terminal Ileum	2	0.434	1.9
GTEx	Spleen	3	0.213	1.8
GTEx	Stomach	3	0.206	1.8
GTEx	Testis	4	0.127	1.7
GTEx	Thyroid	3	0.075	1.7
GTEx	Uterus	2	0.353	1.9
GTEx	Vagina	2	0.315	2.0
GTEx	Whole Blood	1	0.050	1.7
METSIM	Adipose	1	0.022	1.6
NTR	Blood	2	0.083	1.6
ROSMAP	Brain Pre-frontal Cortex	11	0.251	1.8
YFS	Blood	2	0.043	1.5
CommonMind	Brain Pre-frontal Cortex	3	0.056	1.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	3	0.068	1.6
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Colon Adenocarcinoma	4	0.194	1.6
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.438	1.9
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.6
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	5	0.184	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	5	0.122	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	4	0.195	1.6
The Cancer Genome Atlas	Brain Lower Grade Glioma	4	0.093	1.6
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	6	0.204	1.6
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	5	0.200	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	3	0.188	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	1	0.060	1.7
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	2	0.151	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	6	0.130	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Soft Tissue Sarcoma	2	0.187	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.5
The Cancer Genome Atlas	Stomach Adenocarcinoma	4	0.238	1.6
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.156	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	4	0.078	1.6
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.5